Ifenprodil acts as an antagonist at the N-methyl-D-aspartate (NMDA) receptor. These receptors are glutamate receptors and ion channel proteins in nerve cells, and are potential drug targets for neurodegeneration, analgesia, memory disorders, and Parkinson's disease.

We offer both agonist and antagonist radioligands for autoradiographic visualization or performing saturation and competition assays to determine receptor expression levels (B_max), dissociation constants (K_d), association and dissociation rates (k_on and k_off), and inhibitor constants (K_i) for a variety of receptors. We develop our radioligands to the highest specific activity possible and provide high purity resulting in low non-specific binding products. Each of our ultra-pure radioligands is fully characterized for pharmacological action and validated in receptor binding assays.

Radiolabeled ligands remain the most sensitive method for probing receptor binding biology; yielding unprecedented sensitivity gives results that technicians and scientists can trust. For over 50 years, Revvity has been a leading supplier of New England Nuclear (NEN) radiochemicals, liquid scintillation cocktails, vials and nuclear counting detection instruments.

References for NET1089:

1. Jukka Kupila, Olli Kärkkäinen, Virpi Laukkanen, Merja Häkkinen, Hannu Kautiainen, Jari Tiihonen, Markus Storvik, [3H]Ifenprodil binding in post-mortem brains of Cloninger type 1 and 2 alcoholics: A whole-hemisphere autoradiography study, In Psychiatry Research: Neuroimaging, Volume 231, Issue 3, 2015, Pages 197-201.
2. Z. Kawakami, H. Kanno, T. Ueki, K. Terawaki, M. Tabuchi, Y. Ikarashi, Y. Kase, Neuroprotective effects of yokukansan, a traditional japanese medicine, on glutamate-mediated excitotoxicity in cultured cells, In Neuroscience, Volume 159, Issue 4, 2009, Pages 1397-1407.